Cas:5262-39-5 N-Oxalylglycine manufacturer & supplier

Chemical Name:N-Oxalylglycine

CAS.NO:5262-39-5

Synonyms:N-Oxalylglycine;N-OXALYOLGLYCINE;Glycine, N-(carboxycarbonyl)-;N-(Carboxycarbonyl)glycine;OGA;Oxaloglycine;N-oxalyl glycine,1a;2-oxo-3-azaglutaric acid;2-(carboxymethylamino)-2-oxoacetic acid;N-Hydroxyoxalyl-glycin;N-hydroxyoxalyl-glycine;Oxalylglycine

Molecular Formula:C₄H₅NO₅

Molecular Weight:147.086

HS Code:2918300090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.6±0.1 g/cm3

Index of Refraction:1.521

PSA:103.70000

Exact Mass:147.016769

LogP:-1.61

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-Oxalylglycine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Oxalylglycine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-Oxalylglycine Use and application,N-Oxalylglycine technical grade,usp/ep/jp grade.

Related News: Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. N-Oxalylglycine manufacturer “Whenever a company hires outside counsel to conduct an inquiry, it’s taken extremely seriously by the Justice Department,” said Paul Pelletier, a former long-time federal prosecutor who used to oversee criminal investigations of corporations. N-Oxalylglycine supplier We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua��s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. N-Oxalylglycine vendor Madeleine Roche, Associate Pharmaceutical Analyst at GlobalData, comments: ��Within the top 20 global companies that spent the most on R&D in 2018, the top spender �C despite having the second smallest annual revenue of the group at $15.28 billion �C is Celgene, whose R&D spend was equal to 37% of its annual revenue. N-Oxalylglycine factory Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported.